Skip to content

Study · Not a test of the peptide alone · 1990

3 results

[The treatment of women with dyshormonal myocardiodystrophy].

Iakimenko-Vasiutina EA

Vrachebnoe delo1 Aug 1990

PMID2256296 (opens in a new tab)PepBankPUB-02256296
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymalin.

  1. 01HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome

    In women with dyshormonal myocardiodystrophy, cryogenic treatment with thymalin affected extracardiac manifestations, but the abstract's wording leaves the direction unclear.

    In plain wordsIn women with dyshormonal myocardiodystrophy, cryogenic treatment with thymalin affected symptoms outside the heart, but the direction was unclear.

    Peptide
    Thymalin
    Outcome
    Direction not reportedExtracardiac manifestations
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Cardiovascular

    Source sentences

    Summary
    This treatment proved efficient and furthered significant reduction of disappearance of both extracardiac manifestations of the disease.
    1 context sentence
    Summary · context
    Cryogenic treatment in association with thymalin was used in women suffering of dyshormonal myocardiodystrophy associated with hyperplastic processes of the uterus.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  2. 02HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome

    In women with dyshormonal myocardiodystrophy, cellular immunity indices were restored during cryogenic treatment with thymalin.

    In plain wordsIn women with dyshormonal myocardiodystrophy, cryogenic treatment with thymalin restored cellular immunity measures.

    Peptide
    Thymalin
    Outcome
    Direction not reportedCellular immunity indices
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Under the effect of thymalin indices of cellular and humoral immunity were restored.
    1 context sentence
    Summary · context
    Cryogenic treatment in association with thymalin was used in women suffering of dyshormonal myocardiodystrophy associated with hyperplastic processes of the uterus.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  3. 03HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome

    In women with dyshormonal myocardiodystrophy, humoral immunity indices were restored during cryogenic treatment with thymalin.

    In plain wordsIn women with dyshormonal myocardiodystrophy, cryogenic treatment with thymalin restored humoral immunity measures.

    Peptide
    Thymalin
    Outcome
    Direction not reportedHumoral immunity indices
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Under the effect of thymalin indices of cellular and humoral immunity were restored.
    1 context sentence
    Summary · context
    Cryogenic treatment in association with thymalin was used in women suffering of dyshormonal myocardiodystrophy associated with hyperplastic processes of the uterus.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.